- Home
- DATS vs TOVX Comparison
DATS vs TOVX Comparison
Compare DATS & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- TOVX
- Stock Information
- Founded
- DATS 2014
- TOVX 2001
- Country
- DATS United States
- TOVX United States
- Employees
- DATS N/A
- TOVX N/A
- Industry
- DATS Computer Software: Prepackaged Software
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- DATS Technology
- TOVX Health Care
- Exchange
- DATS Nasdaq
- TOVX Nasdaq
- Market Cap
- DATS 5.2M
- TOVX 4.7M
- IPO Year
- DATS 2021
- TOVX 2006
- Fundamental
- Price
- DATS $2.73
- TOVX $1.55
- Analyst Decision
- DATS
- TOVX Strong Buy
- Analyst Count
- DATS 0
- TOVX 1
- Target Price
- DATS N/A
- TOVX $6.00
- AVG Volume (30 Days)
- DATS 1.2M
- TOVX 136.3K
- Earning Date
- DATS 03-28-2025
- TOVX 03-24-2025
- Dividend Yield
- DATS N/A
- TOVX N/A
- EPS Growth
- DATS N/A
- TOVX N/A
- EPS
- DATS N/A
- TOVX N/A
- Revenue
- DATS $515.00
- TOVX N/A
- Revenue This Year
- DATS N/A
- TOVX N/A
- Revenue Next Year
- DATS N/A
- TOVX N/A
- P/E Ratio
- DATS N/A
- TOVX N/A
- Revenue Growth
- DATS N/A
- TOVX N/A
- 52 Week Low
- DATS $1.01
- TOVX $1.14
- 52 Week High
- DATS $9.34
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- DATS 45.64
- TOVX 52.70
- Support Level
- DATS $2.32
- TOVX $1.54
- Resistance Level
- DATS $4.13
- TOVX $1.75
- Average True Range (ATR)
- DATS 0.47
- TOVX 0.13
- MACD
- DATS -0.05
- TOVX 0.02
- Stochastic Oscillator
- DATS 22.65
- TOVX 66.67
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts, even after they are sent.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.